Company Overview and News

2
FI / Frank's International NV 8-K (Current Report)

2018-06-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FI

6
Frank’s International Announces Key Senior Management Promotions, Hires and Related Personnel Changes

2018-06-13 globenewswire
HOUSTON, June 13, 2018 (GLOBE NEWSWIRE) -- Frank’s International N.V. (NYSE:FI) (the “Company” or “Frank’s”) and its Board of Supervisory Directors today announced several key senior management promotions, hires and related personnel changes.
TESO NOC SLB FI SCL TSCDY SLB TSCDF TSCO

1
FI / Frank's International NV 8-K (Current Report)

2018-05-30 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FI

1
Frank's International (FI) CEO Mike Kearney on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Welcome to the Q1 2018 Frank's International N.V. Earnings Conference Call. My name is James, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session [Operator Instructions]. Note this conference is being recorded.
FI

2
FI / Frank's International NV 10-Q (Quarterly Report)

2018-05-08 sec.gov
Document UNITED STATES
FI

1
FI / Frank's International NV 8-K (Current Report)

2018-05-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
FI

1
Frank’s International N.V. Announces First Quarter 2018 Results

2018-05-08 globenewswire
HOUSTON, May 08, 2018 (GLOBE NEWSWIRE) -- Frank’s International N.V. (NYSE:FI) (the “Company” or “Frank’s”) today reported revenues of $115.6 million and a net loss of $42.1 million, or $0.19 per share, for the three months ended March 31, 2018. Adjusted net loss per diluted share for the first quarter was $0.18, excluding $1.1 million in severance and other items, net of tax. Adjusted EBITDA for the quarter was a loss of $2.
FI

1
Frank’s International N.V. Schedules First Quarter 2018 Earnings Release and Conference Call

2018-04-24 globenewswire
HOUSTON, April 24, 2018 (GLOBE NEWSWIRE) -- Frank’s International N.V. (the “Company”) (NYSE:FI) announced today that it will host a conference call to discuss its first quarter 2018 results on Tuesday, May 8, 2018 at 10:00 a.m. Central Time (11:00 a.m. Eastern Time). The Company will issue its first quarter 2018 earnings release prior to the conference call.
FI

1
FI / Frank's International NV DEFA14A

2018-04-09 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FI

1
FI / Frank's International NV DEF 14A

2018-03-28 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20
FI

1
FI / Frank's International NV DEFA14A

2018-03-28 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FI

1
Frank’s International N.V. to Participate in Upcoming Investor Conference

2018-03-22 globenewswire
HOUSTON, March 22, 2018 (GLOBE NEWSWIRE) -- Frank’s International N.V. (NYSE:FI) (the “Company”) announced today that the Company will participate in the following upcoming investor conference.
FI

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

1h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to FI / Frank's International NV on message board site Silicon Investor.

Fidelity Select Funds Fidelity Funds
Point and Figure Charting Canadian Diamond Play Cafi
Mozilla: Firefox and Thunderbird Discussion ... The Financial Collapse of 2001 Unwinding
PFE (Pfizer) How high will it go? Infinera
biotech fireworks Bottom Fish Stocks (Between .05 and $5)
CUSIP: N33462107